Autres langues Aquestive Therapeutics, Inc.

Actions

AQST

US03843E1047

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
4,610 ^USD	+0,88%		-2,95%	-28,64%

29/09	Aquestive Therapeutics, Inc. annonce la nomination de Richard J. Daly au conseil d’administration, avec prise d’effet le 14 octobre 2026	CI
17/09	Aquestive Therapeutics dépose à nouveau sa demande d'autorisation de mise sur le marché auprès de la FDA pour le film sublingual Anaphylm (dibutépinéphrine)	CI

Autres langues

29/09	Aquestive Therapeutics, Inc. Announces Appointment of Richard J. Daly as Director, Effective October 14, 2026
29/09	Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
17/09	Aquestive Therapeutics Resubmits New Drug Application to FDA for Anaphylm (Dibutepinephrine) Sublingual Film
17/09	Aquestive Therapeutics Resubmits Anaphylm NDA to FDA
17/09	Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
01/09	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
11/08	Aquestive Therapeutics Q2 Loss Widens, Revenue Rises
11/08	Aquestive Therapeutics: Q2 Earnings Snapshot
11/08	Aquestive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
11/08	Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08	Aquestive Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year of 2026
11/08	Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film
10/08	Aquestive Therapeutics Shares Rise After Positive Topline Results for Anaphylm Sublingual Film
10/08	Aquestive Therapeutics' Potential Allergy Film Shows Improvements in Human Factors Study
10/08	Aquestive Therapeutics, Inc. Announces Positive Topline Human Factors And Pharmacokinetic Study Results For Anaphylm Sublingual Film
10/08	Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
29/07	Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
29/07	Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
07/07	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
13/05	Aquestive Therapeutics Inc - enters five-year term loan facility of up to $150 million on May 12, 2026 - SEC filing
13/05	Aquestive Therapeutics: Q1 Earnings Snapshot
13/05	Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
13/05	Aquestive Therapeutics, Inc. Reaffirm Earnings Guidance for the Full Year 2026
12/05	Aquestive Therapeutics Signs New $150 Million Debt Facility